Ki-67 as a Prognostic Factor in Feline Mammary Carcinoma: What Is the Optimal Cutoff Value?

Veterinary Pathology

Volumn 53, Issue 1, 2016, Pages 37-43

  Soares, M ^a   Ribeiro, R ^a   Carvalho, S ^a   Peleteiro, M ^a   Correia, J ^a   Ferreira, F ^a  

^a FACULDADE DE MEDICINA VETERINÁRIA   (Portugal)

Author keywords

cutoff value; feline mammary carcinoma; Ki 67 proliferation index; prognostic factor

Indexed keywords

KI 67 ANTIGEN; TUMOR MARKER;

ANIMAL; BREAST TUMOR; CARCINOMA; CAT; CAT DISEASE; FEMALE; LYMPH NODE METASTASIS; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY;

ANIMALS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA; CAT DISEASES; CATS; FEMALE; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84952002585     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985815588606     Document Type: Article

References (45)

1. A.AdamczykJ.NiemiecA.Ambicka. Expression of ER/PR/HER2, basal markers and adhesion molecules in primary breast cancer and in lymph nodes metastases: a comparative immunohistochemical analysis. Pol J Pathol. 2012;63:226–234.
2. B.BrunettiP.AsproniG.Beha. Molecular phenotype in mammary tumours of queens: correlation between primary tumour and lymph node metastasis. J Comp Pathol. 2013;148:206–213.
3. G.P.BurraiS.I.MohammedM.A.Miller. Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions. BMC Cancer. 2010;10:156.
4. M.CastagnaroR.De MariaE.Bozzetta. Ki-67 index as indicator of the post-surgical prognosis in feline mammary carcinomas. Res Vet Sci. 1998;65(3):223–226.
5. M.C.U.CheangS.K.ChiaD.Voduc. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–750.
6. A.DeCensiA.Guerrieri-GonzagaS.Gandini. Prognostic significance of Ki-67 labeling índex after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol. 2011;22:582–587.
7. C.DenkertS.LoiblB.M.Müller. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol. 2013;24(11):2786–2793.
8. B.DeyarminJ.L.KaneA.L.Valente. Effect of ASCO/CAP guidelines for determining ER status on Molecular subtype. Ann Surg Oncol. 2013;20(1):87–93.
9. M.DowsettT.O.NielsenR.A’Hern. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2011;103:1656–1664.
10. C.W.ElstonI.O.Ellis. Assessment of histological grade. In: P.P.Rosen, ed. Rosen’s Breast Pathology. Philadelphia, PA: Lippincott-Raven; 1998:365–382.
11. P.A.FaschingK.HeusingerL.Haeberle. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011;11:486.
12. A.GoldhirschE.P.WinerA.S.Coates. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206–2223.
13. M.E.HammondD.F.HayesM.Dowsett. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):48–72.
14. L.HarrisH.FritscheR.Mennel. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–5312.
15. J.M.HarveyG.M.ClarkC.K.Osborne. Estrogen Receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474–1481.
16. K.JoensuuM.LeideniusM.Kero. ER, PR, HER2, Ki-67 and Ck5 in early and late relapsing breast cancer: reduced Ck5 expression in metastases. Breast Cancer (Auckl). 2013;7:23–34.
17. B.KeamS.A.ImK.H.Lee. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 2011;13:R22.
18. E.LuporsiF.AndreF.Spyratos. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat. 2012;132:895–915.
19. E.G.MacEwenA.A.HayesH.J.Harvey. Prognostic factors for feline mammary tumors. J Am Vet Med Assoc. 1984;185(2):201–204.
20. S.MénardE.TagliabueM.Campiglio. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol. 2000;182(2):150–162.
21. F.MillantaM.CalandrellaS.Citi. Overexpression of HER-2 in feline invasive mammary carcinomas: na immunohistochemical survey and evaluation of its prognostic potential. Vet Pathol. 2005;42:30–34.
22. F.MillantaM.CalandrellaI.Vannozzi. Steroid hormone receptors in normal, dysplastic and neoplastic feline mammary tissues and their prognostic significance. Veterinary Record. 2006;158:821–824.
23. F.MillantaG.LazzeriM.Mazzei. MIB-1 labeling index in feline dysplastic and neoplastic mammary lesions and its relationship with postsurgical prognosis. Vet Pathol. 2002;39:120–126.
24. W.MisdorpR.W.ElseE.Hellmen. Histologic classification of mammary tumors of the dog and the cat. In: World Health Organization international histological classification of tumours of domestic animals. 2nd ed. Vol 7. Washington, DC: Armed Force Institute of Pathology; 1999:11–27.
25. S.K.MohsinH.WeissT.Havighurst. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17:1545–1554.
26. S.OhnoL.W.C.ChowN.Sato. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5–fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013;142:69–80.
27. M.OnoH.TsudaM.Yunokawa. Prognostic impact of Ki-67 labeling indices with 3 different cut-off values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers. Breast Cancer. 2013;22:141–152.
28. S.ParkJ.S.KooM.S.Kim. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by panel of four biomarkers using immunohistochemistry. Breast. 2012;21:50–57.
29. N.PathmanathanR.L.Balleine. Ki67 and proliferation in breast cancer. J Clin Pathol. 2013;66:512–516.
30. P.D.PereiraJ.CarvalheiraF.Gärtner. Cell proliferation in feline normal, hyperplastic and neoplastic mammary tissue: an immunohistochemical study. Vet J. 2004;168:180–185.
31. C.M.PerouT.SurlieM.B.Eisen. Molecular portraits of human breast tumours. Nature. 2000;406:747–752.
32. R.PreziosiG.SarliC.Benazzi. Multiparametric survival analysis of histological stage and proliferative activity in feline mammary carcinomas. Res Vet Sci. 2002;73:53–60.
33. R.RasottoD.CaliariM.Castagnaro. An immunohistochemical study of HER-2 expression in feline mammary tumours. J Comp Path. 2011;144(2–3):170–179.
34. A.RoccaS.BravacciniE.Scarpi. Benefit from anthracyclines in relation to biological profiles in early breast cancer. Breast Cancer Res Treat. 2014;144(2):307–318.
35. S.SantosC.BaptistaR.M.V.Abreu. ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancer. Plos One. 2013;8(12):e83673.
36. F.SassiC.BenazziG.Castellani. Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry. BMC Vet Res. 2010;6:5.
37. F.SeixasC.PalmeiraM.A.Pires. Grade is an independent prognostic factor for feline mammary carcinomas: a clinicopathological and survival analysis. Vet J. 2011;187(1):65–71.
38. M.SoaresJ.CorreiaP.Rodrigues. Feline HER2 protein expression levels and gene status in feline mammary carcinoma: optimization of immunohistochemistry (IHC) and in situ hybridization (ISH) techniques. Microsc Microanal. 2013;19:1–7.
39. K.U.SorenmoD.R.WorleyM.H.Goldschmidt. Tumors of the mammary gland. In: S.J.WithrowD.M.VailR.L.Page, eds. Small Animal Clinical Oncology. 5th ed. Missouri, MO: Saunders; 2013:538–556.
40. Q.X.TanQ.H.QinW.P.Yang. Prognostic value of Ki-67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Int J Clin Exp Pathol. 2014;7:6862–6870.
41. T.TaneiA.ShimomuraK.Shimazu. Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer. EJSO. 2011;37:155–161.
42. M.VascellariE.BaioniG.Ru. Animal tumour registry of two provinces in northern Italy: incidence of spontaneous tumours in dogs and cats. BMC Vet Res. 2009;5:39.
43. K.WeijerA.A.M.Hart. Prognostic factors in feline mammary carcinoma. J Natl Cancer Inst. 1983;70:709–716.
44. A.C.WolffM.E.HammondD.G.Hicks. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4014.
45. R.YerushalmiR.WoodsP.M.Ravdin. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174–183.